Summit Therapeutics (NASDAQ:SMMT) Hits New 52-Week Low – What’s Next?

Summit Therapeutics PLC (NASDAQ:SMMT – Get Free Report) shares reached a new 52-week low on Monday. The stock traded as low as $12.01 and last traded at $12.6040, with a volume of 1,698,713 shares traded. The stock had previously closed at $14.15.

Trending Headlines about Summit Therapeutics

Investors following SMMT have been watching these headlines:

Analysts Set New Price Targets

Several brokerages recently issued reports on SMMT. The Goldman Sachs Group set a $41.00 price target on shares of Summit Therapeutics and gave the company a “buy” rating in a report on Tuesday, September 29th. Morgan Stanley cut shares of Summit Therapeutics to an “outperform” rating in a research note on Tuesday, September 29th. Wall Street Zen raised shares of Summit Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, September 5th. UBS Group reaffirmed a “neutral” rating on shares of Summit Therapeutics in a report on Wednesday, September 23rd. Finally, HC Wainwright reiterated a “buy” rating on shares of Summit Therapeutics in a research note on Thursday, October 15th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Summit Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $28.61.

Get Our Latest Analysis on Summit Therapeutics

Summit Therapeutics Trading Down 9.1%

The firm has a fifty day simple moving average of $16.41 and a 200-day simple moving average of $16.14. The stock has a market cap of $10.28 billion, a price-to-earnings ratio of -11.99 and a beta of -1.49.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. BlackRock Inc. acquired a new stake in shares of Summit Therapeutics during the 2nd quarter worth approximately $138,838,000. Candriam S.C.A. lifted its holdings in Summit Therapeutics by 212.3% in the third quarter. Candriam S.C.A. now owns 1,662,969 shares of the company’s stock valued at $28,224,000 after buying an additional 1,130,537 shares during the period. Bank of America Corp DE acquired a new position in Summit Therapeutics in the second quarter valued at approximately $12,603,000. The Manufacturers Life Insurance Company lifted its holdings in Summit Therapeutics by 34.4% in the first quarter. The Manufacturers Life Insurance Company now owns 592,810 shares of the company’s stock valued at $11,240,000 after buying an additional 151,857 shares during the period. Finally, Simplify Asset Management Inc. bought a new position in Summit Therapeutics in the third quarter valued at approximately $8,626,000. 4.61% of the stock is currently owned by institutional investors and hedge funds.

Summit Therapeutics Company Profile

(Get Free Report)

Summit Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Its lead candidate is ivonescimab, a bispecific antibody designed to target both PD-1 and VEGF, two pathways involved in tumor growth and the immune response. The company is evaluating the treatment in clinical trials for multiple types of cancer. Summit licensed rights to develop and commercialize ivonescimab from China-based Akeso in 2022. Summit’s licensed territory covers markets outside China, including the United States, Canada, Europe and Japan.

Featured Articles

Receive News & Ratings for Summit Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.